RxDoctor Payments Data

Jennifer Olivier, APRN

Gerontology · Little Rock, ARNPI 1235818311

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations.

$605in general payments, 2019–2025

Across 34 payments — averaging $17.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$119
  • AbbVie$105
  • Pfizer$92
  • Novo Nordisk$53
  • Exact Sciences$53
  • Bayer$34
  • plus $150 from 7 others

What the payments were for

  • Food & beverage$605100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$605 in reported general payments places this provider in the 60th percentile of 89 gerontology providers in Arkansas.

See all gerontology providers in Arkansas

Medicare billing

Part B allowed, 2024
$19,385
Medicare patients
184
Services billed
309

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab73$633,453
CopaxoneGlatiramer Acetate58$348,044
TecfideraDimethyl Fumarate24$211,423
EnspryngSatralizumab-Mwge12$193,748
VumerityDiroximel Fumarate22$188,344
Avonex (4 Pack)Interferon Beta-1a22$170,800
Glatiramer Acetate25$51,646
Teriflunomide72$51,413
Dalfampridine ErDalfampridine141$39,243
Aimovig AutoinjectorErenumab-Aooe24$24,807
FingolimodFingolimod Hcl34$24,700
Nurtec OdtRimegepant Sulfate14$23,907
Modafinil68$13,962
MyrbetriqMirabegron17$9,481
Dimethyl Fumarate39$6,334

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$92$23,90714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 89 gerontology providers in Arkansas.

Other gerontology in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →